Company news

Viatris Inc. news in 2025

Viatris Inc.'s news releases, calls and decks from 2025, newest first.

View company

Viatris Provides Pipeline Update on Four Regulatory Milestones

December 17, 2025

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back

December 15, 2025

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

December 5, 2025

Viatris to Participate in Upcoming Investor Conferences

November 23, 2025

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 20, 2025

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

November 12, 2025

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

November 5, 2025

Policy Engagement to Break Down Barriers to Access and Build Resilient Health Systems at Viatris

November 4, 2025

Viatris Announces Quarterly Dividend

November 3, 2025

Collaborating to Address Antimicrobial Resistance at Viatris

October 28, 2025

How Viatris is Fighting Infectious Disease

October 21, 2025

How Viatris Prevents and Manages NCDs

October 15, 2025

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

October 14, 2025

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

October 7, 2025

Viatris’ Work To Advance Access and Public Health

October 7, 2025

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

September 30, 2025

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

August 18, 2025

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

August 10, 2025

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

August 6, 2025

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

August 4, 2025

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

July 31, 2025

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

July 17, 2025

Viatris Certified as a Great Place to Work® in Canada

July 15, 2025

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

June 25, 2025

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

June 11, 2025

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

June 1, 2025

Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada

May 27, 2025

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

May 7, 2025

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

May 7, 2025

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

May 7, 2025

Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

May 4, 2025

Viatris to Present at the BofA Securities 2025 Healthcare Conference

April 24, 2025

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

April 20, 2025

Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

April 13, 2025

Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

April 6, 2025

Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

March 27, 2025

Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

March 4, 2025

Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance

February 26, 2025

Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend

February 26, 2025

Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 2, 2025

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Calls in 2025

Decks in 2025